Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01205087
NCT01205087CompletedPhase 2

Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody in Patients With the Metabolic Syndrome PHASE IIa A Single-blinded Placebo-controlled Clinical Trial

Hadassah Medical Organization1 site in 1 country36 target enrollmentStarted: September 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
36
Locations
1
Primary Endpoint
This clinical study is designed to evaluate the safety and the immune-modulatory effects of oral administration of the study drug anti-CD3 MAb to subjects with the metabolic syndrome.
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This clinical study is designed to evaluate the safety and immune modulatory effects of oral administration of the study drug anti-CD3 monoclonal antibody (MAb) to subjects with the metabolic syndrome.

Detailed Description

PHASE IIa STUDY PROTOCOL A Single-blinded Placebo-controlled Clinical Trial.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subjects who have completed the informed consent process culminating with written informed consent by the subject.
  • •Men and women age 18 to 75 years (inclusive)
  • •Patients with biopsy proven NASH within the last 3 years
  • •Altered glucose metabolism, including diabetes (non treated, or treated with up to 2 drugs (not including insulin) without any change in medication for at least 2 months prior to enrollment), impaired fasting glucose or impaired glucose tolerance.
  • •HBA1C between 5.5 and 14%.

Exclusion Criteria

  • •Subjects who have undergone surgery within the last 3 months.
  • •Subjects who have had a prior gastrointestinal surgery.
  • •Subjects with a clinically significant infectious, immune mediated or malignant disease
  • •Subjects who are receiving an elemental diet or parenteral nutrition.
  • •Subjects who have been treated with any type of immune modulatory drug including steroids or NSAID within the last 4 weeks
  • •Subjects who have received either methotrexate or cyclosporine or anti TNF-β (infliximab, Remicade), anti-integrin (namixilab) or who have participated in any other clinical trial within the last 3 months.
  • •Subjects with a history of coagulopathy.
  • •Women with childbearing potential unless surgically sterile or using adequate contraception (either IUD, oral or Depo-provera contraceptive, or barrier plus spermicide); pregnant or breastfeeding mothers.
  • •Subjects, who will be unavailable for the duration of the trial, are unlikely to be compliant with the protocol, or who are felt to be unsuitable by the investigator for any other reason.
  • •Subjects who are HIV-positive.
  • •Subjects who are HBV-positive
  • •Subjects who are HCV-positive.
  • •Subjects with active CMV
  • •Subjects with anemia (Hb <10.5 gm/dl).
  • •Subjects with thrombocytopenia (platelets <100K/µl).
  • •Subjects with lymphopenia (absolute lymphocyte count <0.7).
  • •Subjects with IgG anti-cardiolipin antibody >16 IU.
  • •Prior exposure to anti-CD3 MAb.
  • •Known sensitivity to any ingredients in the study drug
  • •Any know autoimmune disease except for the studied disorders.

Arms & Interventions

Placebo

Placebo Comparator

Intervention: OKT3 (Drug)

OKT3 - 0.2

Active Comparator

Intervention: OKT3 (Drug)

OKT3 - 1

Active Comparator

Intervention: OKT3 (Drug)

OKT3 - 5

Active Comparator

Intervention: OKT3 (Drug)

Outcomes

Primary Outcomes

This clinical study is designed to evaluate the safety and the immune-modulatory effects of oral administration of the study drug anti-CD3 MAb to subjects with the metabolic syndrome.

Time Frame: 60 days

Secondary Outcomes

  • This clinical study also will include evaluations for markers of efficacy, as described below.(60 days)

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials

Withdrawn
Phase 2
Safety and Validation of Efficacy of Oral Administration of the Food Additive Colostrum Derived Anti Clostridium Difficile AntibodiesClostridium Difficile-Associated Diarrhea
NCT00747071Hadassah Medical Organization
Terminated
Phase 2
Study of FK778 in Renal Transplant Recipients With Untreated BK NephropathyBK PolyomavirusKidney Diseases
NCT00104338Astellas Pharma Inc45
Recruiting
Phase 3
Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKDGlomerulonephritis, IGA
NCT05510323Air Force Military Medical University, China208
Completed
Phase 2
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)Clostridium Difficile Infection
NCT02092935Summit Therapeutics100
Not yet recruiting
Not Applicable
Efficacy and safety of oral immunotherapy combination with omalizumab for severe cow&#39;s milk allergy- follow up studyfood allergy
JPRN-UMIN000024397Kansai Medical University15